Citadel Advisors - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 132 filers reported holding REVANCE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.5%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,265,487
-27.6%
371,882
+59.7%
0.00%
-100.0%
Q2 2023$5,892,143
-11.1%
232,799
+13.1%
0.00%0.0%
Q1 2023$6,627,208
-6.3%
205,750
-46.3%
0.00%
-50.0%
Q4 2022$7,070,623
-74.6%
383,024
-62.9%
0.00%
-71.4%
Q3 2022$27,842,000
+124.6%
1,031,169
+15.0%
0.01%
+133.3%
Q2 2022$12,395,000
-25.2%
896,984
+5.5%
0.00%0.0%
Q1 2022$16,574,000
+525.4%
849,893
+423.5%
0.00%
Q4 2021$2,650,000
-74.7%
162,358
-56.8%
0.00%
-100.0%
Q3 2021$10,466,000
-21.6%
375,672
-16.6%
0.00%
-33.3%
Q2 2021$13,356,000
+54.8%
450,620
+46.0%
0.00%
+50.0%
Q1 2021$8,626,000
-25.5%
308,600
-24.5%
0.00%
-33.3%
Q4 2020$11,585,000
-26.9%
408,783
-35.1%
0.00%
-25.0%
Q3 2020$15,843,000
+932.1%
630,182
+902.7%
0.00%
Q2 2020$1,535,000
+46.2%
62,847
-11.3%
0.00%
Q1 2020$1,050,000
+33.4%
70,879
+46.0%
0.00%
Q4 2019$787,000
-65.1%
48,536
-72.0%
0.00%
-100.0%
Q3 2019$2,255,000
+13.3%
173,452
+13.1%
0.00%0.0%
Q2 2019$1,990,000
-45.7%
153,423
-34.0%
0.00%
-50.0%
Q1 2019$3,664,000
+703.5%
232,551
+925.0%
0.00%
Q4 2018$456,000
-85.7%
22,689
-82.3%
0.00%
-100.0%
Q3 2018$3,186,000
-35.9%
128,169
-29.3%
0.00%
-50.0%
Q2 2018$4,974,000
+57.7%
181,197
+76.9%
0.00%
+100.0%
Q1 2018$3,154,000
+28.7%
102,411
+49.4%
0.00%0.0%
Q4 2017$2,451,000
+453.3%
68,554
+325.8%
0.00%
Q3 2017$443,000
+108.0%
16,100
+32.2%
0.00%
Q1 2016$213,000
-71.9%
12,178
-48.5%
0.00%
-100.0%
Q2 2015$757,000
-10.5%
23,656
-52.7%
0.00%0.0%
Q4 2014$846,000
+58.7%
49,974
+81.4%
0.00%0.0%
Q3 2014$533,000
-87.5%
27,554
-78.0%
0.00%
-80.0%
Q2 2014$4,260,000
+67.8%
125,289
+55.4%
0.01%
+66.7%
Q1 2014$2,539,00080,6000.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders